BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jung YS, Park CH, Park JH, Nam E, Lee HL. Efficacy of Helicobacter pylori eradication therapies in Korea: A systematic review and network meta-analysis. Helicobacter. 2017;22. [PMID: 28425141 DOI: 10.1111/hel.12389] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Kim BJ, Yang CH, Song HJ, Jeon SW, Kim GH, Kim HS, Kim TH, Shim KN, Chung IK, Park MI, Choi IJ, Kim JH, Kim BW, Baik GH, Han SW, Seo HE, Jung WT, Hwan Oh J, Kim SG, Lee JH, Park SK, Park BJ, Yang BR, Lee J, Kim JG. Online registry for nationwide database of Helicobacter pylori eradication in Korea: Correlation of antibiotic use density with eradication success. Helicobacter. 2019;24:e12646. [PMID: 31368629 DOI: 10.1111/hel.12646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
2 Kaplan M, Tanoglu A, Duzenli T, Tozun AN. Helicobacter pylori treatment in Turkey: Current status and rational treatment options. North Clin Istanb 2020;7:87-94. [PMID: 32232212 DOI: 10.14744/nci.2019.62558] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
3 Kim SY, Chung JW. Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance. Antibiotics (Basel) 2020;9:E436. [PMID: 32717826 DOI: 10.3390/antibiotics9080436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Gweon TG, Kim JS, Kim BW. An Economic Modeling Study of Helicobacter pylori Eradication: Comparison of Dual Priming Oligonucleotide-Based Multiplex Polymerase Chain Reaction and Empirical Treatment. Gut Liver 2018;12:648-54. [PMID: 30037167 DOI: 10.5009/gnl18079] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
5 Park JY, Kim JG. [New Helicobacter pylori Eradication Therapies]. Korean J Gastroenterol 2018;72:237-44. [PMID: 30642139 DOI: 10.4166/kjg.2018.72.5.237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Jung HK, Kang SJ, Lee YC, Yang HJ, Park SY, Shin CM, Kim SE, Lim HC, Kim JH, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M; Korean College of Helicobacter and Upper Gastrointesinal Research. Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020. Korean J Intern Med 2021;36:807-38. [PMID: 34092054 DOI: 10.3904/kjim.2020.701] [Reference Citation Analysis]
7 Kim BJ, Lee H, Lee YC, Jeon SW, Kim GH, Kim HS, Sung JK, Lee DH, Kim HU, Park MI, Choi IJ, Yoon SM, Kim SW, Baik GH, Lee JY, Kim JI, Kim SG, Kim J, Lee J, Kim JG, Kim JJ;  Korean College of Helicobacter Upper Gastrointestinal Research. Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for Helicobacter pylori Infection: A Nationwide Randomized Trial in Korea. Gut Liver. 2019;13:531-540. [PMID: 31505907 DOI: 10.5009/gnl19136] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 12.5] [Reference Citation Analysis]
8 O'Connor A, Lamarque D, Gisbert JP, O'Morain C. Treatment of Helicobacter pylori infection 2017. Helicobacter 2017;22 Suppl 1. [PMID: 28891137 DOI: 10.1111/hel.12410] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
9 Choe AR, Shim KN, Park Y, Song EM, Tae CH, Jung SA. Cost-Effectiveness, Efficacy, and Safety Analysis of Tailored Therapy in Patients with Helicobacter pylori Infection. J Clin Med 2021;10:2619. [PMID: 34198677 DOI: 10.3390/jcm10122619] [Reference Citation Analysis]
10 Kim EH, Park CH. Vonoprazan-Based Helicobacter pylori Eradication Therapy: Time to Get Kompetitive? Dig Dis Sci 2017;62:2955-7. [DOI: 10.1007/s10620-017-4699-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
11 Park JY, Shin TS, Kim JH, Yoon HJ, Kim BJ, Kim JG. The Prevalence of Multidrug Resistance of Helicobacter pylori and Its Impact on Eradication in Korea from 2017 to 2019: A Single-Center Study. Antibiotics (Basel) 2020;9:E646. [PMID: 32992624 DOI: 10.3390/antibiotics9100646] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Jung HK, Kang SJ, Lee YC, Yang HJ, Park SY, Shin CM, Kim SE, Lim HC, Kim JH, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M;  Korean College of Helicobacter and Upper Gastrointestinal Research. Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020. Gut Liver. 2021;15:168-195. [PMID: 33468712 DOI: 10.5009/gnl20288] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
13 Jung YS, Kim EH, Park CH. Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori -authors’ reply. Aliment Pharmacol Ther 2017;46:551-2. [DOI: 10.1111/apt.14206] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
14 Nam SY, Lee SW, Jeon SW, Kwon YH, Lee HS. Helicobacter pylori Eradication Regressed Gastric Hyperplastic Polyp: A Randomized Controlled Trial. Dig Dis Sci 2020;65:3652-9. [DOI: 10.1007/s10620-020-06065-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
15 Jin BH, Yoo BW, Park J, Kim JH, Lee JY, Shin JS, Park MS. Pharmacokinetic drug interaction and safety after coadministration of clarithromycin, amoxicillin, and ilaprazole: a randomised, open-label, one-way crossover, two parallel sequences study. Eur J Clin Pharmacol 2018;74:1149-57. [PMID: 29846770 DOI: 10.1007/s00228-018-2489-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Choi YI, Chung JW, Park DK, Kim KO, Kwon KA, Kim YJ, Seo JY. Tailored eradication vs empirical bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication: A comparative, open trial. World J Gastroenterol 2019; 25(46): 6743-6751 [PMID: 31857776 DOI: 10.3748/wjg.v25.i46.6743] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]